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Summary
Background Antiretroviral regimens containing tenofovir disoproxil fumarate have been associated with renal toxicity 
and reduced bone mineral density. Tenofovir alafenamide is a novel tenofovir prodrug that reduces tenofovir plasma 
concentrations by 90%, thereby decreasing off -target side-eff ects. We aimed to assess whether effi  cacy, safety, and 
tolerability were non-inferior in patients switched to a regimen containing tenofovir alafenamide versus in those 
remaining on one containing tenofovir disoproxil fumarate.
Methods In this randomised, actively controlled, multicentre, open-label, non-inferiority trial, we recruited 
HIV-1-infected adults from Gilead clinical studies at 168 sites in 19 countries. Patients were virologically suppressed 
(HIV-1 RNA <50 copies per mL) with an estimated glomerular fi ltration rate of 50 mL per min or greater, and were 
taking one of four tenofovir disoproxil fumarate-containing regimens for at least 96 weeks before enrolment. With 
use of a third-party computer-generated sequence, patients were randomly assigned (2:1) to receive a once-a-day 
single-tablet containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 
10 mg (tenofovir alafenamide group) or to carry on taking one of four previous tenofovir disoproxil fumarate-
containing regimens (tenofovir disoproxil fumarate group) for 96 weeks. Randomisation was stratifi ed by previous 
treatment regimen in blocks of six. Patients and treating physicians were not masked to the assigned study regimen; 
outcome assessors were masked until database lock. The primary endpoint was the proportion of patients who 
received at least one dose of study drug who had undetectable viral load (HIV-1 RNA <50 copies per mL) at week 48. 
The non-inferiority margin was 12%. This study was registered with ClinicalTrials.gov, number NCT01815736.
Findings Between April 12, 2013 and April 3, 2014, we enrolled 1443 patients. 959 patients were randomly assigned to 
the tenofovir alafenamide group and 477 to the tenofovir disoproxil fumarate group. Viral suppression at week 48 was 
noted in 932 (97%) patients assigned to the tenofovir alafenamide group and in 444 (93%) assigned to the tenofovir 
disoproxil fumarate group (adjusted diff erence 4·1%, 95% CI 1·6–6·7), with virological failure noted in ten and six 
patients, respectively. The number of adverse events was similar between the two groups, but study drug-related 
adverse events were more common in the tenofovir alafenamide group (204 patients [21%] vs 76 [16%]). Hip and spine 
bone mineral density and glomerular fi ltration were each signifi cantly improved in patients in the tenofovir 
alafenamide group compared with those in the tenofovir disoproxil fumarate group.
Interpretation Switching to a tenofovir alafenamide-containing regimen from one containing tenofovir disoproxil 
fumarate was non-inferior for maintenance of viral suppression and led to improved bone mineral density and renal 
function. Longer term follow-up is needed to better understand the clinical impact of these changes.
Funding Gilead Sciences.
Introduction
Although most patients with HIV-1 infection have 
durable virological suppression with their fi rst anti-
retroviral therapy (ART) regimen, switching to an alter-
native regimen could reduce pill burden or dosing 
frequency, improve adherence and tolerability, and 
reduce toxicity and costs.1  The clinical goal of patients 
switching a treatment regimen is to achieve one or more 
of these advantages, while maintaining virological 
suppression. 
Tenofovir disoproxil fumarate is associated with 
excellent virological suppression, but some patients can 
develop clinically relevant nephrotoxicity over time,2 
especially individuals with risk factors for renal disease.3 
Some patients also have greater reductions in bone 
mineral density with tenofovir disoproxil fumarate than 
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with other ART regimens, especially in the fi rst 24 weeks 
of treatment.4,5 In two double-blind randomised 
controlled studies of tenofovir alafenamide versus 
tenofovir disoproxil fumarate (both added to elvitegravir, 
cobicistat, and emtricitabine) in the initial treatment of 
HIV-1 infection, more than 90% of patients receiving 
tenofovir alafenamide had virological suppression 
at week 48, but renal and bone abnormalities were 
signifi cantly reduced in patients allocated to tenofovir 
alafenamide compared with those allocated to tenofovir 
disoproxil fumarate.6
In this study, we aimed to evaluate whether effi  cacy, 
safety, and tolerability (including bone and renal 
outcomes) were non-inferior in patients switched to a 
single tablet regimen of tenofovir alafenamide plus 
elvitegravir, cobicistat, and emtricitabine, compared with 
patients who remained on one of four regimens 
containing tenofovir disoproxil fumarate.
Methods
Study design and participants
GS-US-292-0109 is a randomised, active-controlled, open-
label, multicentre, non-inferiority study. All patients were 
HIV-1-infected adults drawn from pre defi ned Gilead 
clinical studies at 168 sites in 19 countries in North 
America, Europe, Latin America, Asia, and Australia in 
which patients were taking a tenofovir disoproxil 
fumarate-containing regimen recommended by 
treatment guidelines (appendix).1 All patients were 
virologically suppressed (HIV-1 RNA <50 copies per mL), 
had an estimated glomerular fi ltration (eGFR) rate greater 
than 50 mL per min (calculated by the Cockcroft–Gault 
equation), and all had been on one of four regimens 
containing tenofovir disoproxil fumarate for at least 
96 weeks—elvitegravir, cobicistat, emtricitabine, and 
tenofovir disoproxil fumarate; efavirenz, emtricitabine, 
and tenofovir disoproxil fumarate; cobicistat-boosted 
atazanavir plus emtricitabine and tenofovir disoproxil 
fumarate; or ritonavir-boosted atazanavir plus 
emtricitabine and tenofovir disoproxil fumarate. Written 
consent was obtained by investigators.
Randomisation and masking
We randomly assigned patients (2:1) to either switch to 
elvitegravir, cobicistat, emtricitabine, and tenofovir 
alafenamide (tenofovir alafenamide group) or to stay on 
their previous tenofovir disoproxil fumarate-containing 
regimen (tenofovir disoproxil fumarate group). A 
computer-generated allocation sequence was generated 
by Bracket (San Francisco, CA, USA) and randomisation 
was stratifi ed by previous treatment regimen at screening 
in block sizes of six. Investigators determined eligibility, 
obtained the patient number, and received the treatment 
assignment based on the randomisation sequence. 
Patients and treating physicians were not masked to the 
assigned study regimen; outcome assessors were masked 
until database lock.
Procedures
All study drugs were prescribed to be taken orally once a 
day with food at about the same time each day for each 
patient, apart from efavirenz, emtricitabine, and 
tenofovir disoproxil fumarate, which was prescribed to 
be taken on an empty stomach at the hour of sleep. 
Laboratory analyses (haematology, chemistry, and 
urinalysis; Covance Central Laboratory, Indianapolis, IN, 
Research in context
Evidence before this study
We searched PubMed for articles published in English between 
1970 and June 15, 2015, about the side-eff ects of tenofovir 
disoproxil fumarate-containing treatment. Our search terms 
included “tenofovir”, “creatinine”, “proteinuria”, “tubulopathy”, 
and “bone mineral density”. We reviewed about 50 articles. 
A phase 2 comparative study of tenofovir alafenamide versus 
tenofovir disoproxil fumarate as part of a single-tablet regimen 
with elvitegravir, cobicistat, and emtricitabine showed 
signifi cant improvements in both renal and bone safety for 
patients in the tenofovir alafenamide group.
Added value of this study
This large study in virologically suppressed patients with HIV 
showed non-inferiority for elvitegravir, cobicistat, 
emtricitabine, and tenofovir alafenamide over tenofovir 
disoproxil fumarate-containing regimens on effi  cacy at 
week 48. Importantly, patients who switched to elvitegravir, 
cobicistat, emtricitabine, and tenofovir alafenamide after at 
least 96 weeks on a tenofovir disoproxil fumarate-containing 
regimen had signifi cant improvements in proteinuria, specifi c 
proximal tubular proteinuria, bone mineral density, and 
diagnoses of osteopenia and osteoporosis. These data also 
show that post-switch improvements occur irrespective of the 
third drug used. The improvements in measures of renal and 
bone safety could represent a clinical confi rmation of the eff ect 
of lower plasma tenofovir concentrations in patients switched 
to elvitegravir, cobicistat, emtricitabine, and tenofovir 
alafenamide. Moreover, both the speed of improvement in 
these objective tests (week 2 after the switch) and the 
magnitude of the improvement over time have not been 
previously described.
Implications of all available evidence
Elvitegravir, cobicistat, emtricitabine, and tenofovir 
alafenamide is a highly potent regimen that could be used in 
treatment-naive patients, with or without risk of renal or bone 
comorbidities, and it might be used as a strategic switch in 
patients using tenofovir-containing regimens who want to 
reduce their risk of tenofovir-related renal or bone toxicity.
See Online for appendix
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USA), HIV-1 RNA (Taqman 2·0 assay [Roche, Pleasanton, 
CA, USA]),7 CD4 cell count, and complete or symptom-
directed physical examinations were done at baseline and 
at all subsequent study visits (weeks 2, 4, 8, and 12, and 
then every 12 weeks up to week 96). Dual energy x-ray 
absorptiometry (DXA) scans for hip and spine bone 
mineral density were done before drug administration at 
baseline and then every 24 weeks throughout the study. 
All scans were blindly read by a centralised laboratory 
(BioClinica, Newtown, PA, USA). Blood and urine tests 
for renal and bone biomarkers were done at 
baseline, weeks 2, 4, 12, 24, and 48 and at early study drug 
discontinuation visit. Kidney function tests included 
serum creatinine, eGFR by Cockcroft Gault equation 
(eGFRCG), and eGFR by Chronic Kidney Disease 
Epidemiology Collaboration and creatinine method 
(eGFRCKD-EPI).8–11 Proteinuria was assessed qualitatively by 
dipstick urinalysis, quantitatively by urine protein to 
creatinine ratio, urine albumin to creatinine ratio, and 
specifi c proximal renal tubular proteinuria (retinol 
binding protein to creatinine ratio, β2-microglobulin to 
creatinine ratio); renal function was also assessed by 
renal tubular maximum reabsorption rate of phosphate 
to the glomerular fi ltration rate, fractional excretion of 
phosphate, and fractional excretion of uric acid. Adverse 
events and concomitant drugs were assessed at each 
visit. At 96 weeks, all patients had the option to switch to 
open-label elvitegravir, cobicistat, emtricitabine, and 
tenofovir alafenamide.
Outcomes
The primary effi  cacy endpoint was the proportion of 
patients with HIV-1 RNA of less than 50 copies per mL 
at week 48 after randomisation with use of the US Food 
and Drug Administration (FDA)-defi ned snapshot 
algorithm.12 Prespecifi ed secondary outcomes were 
percentage change in hip and spine bone mineral 
density, change in serum creatinine, and change in 
efavirenz-related symptom score at week 48. Effi  cacy, 
safety, and tolerability were also assessed up to 96 weeks. 
Safety evaluations included standard laboratory testing 
and adverse event, coded with version 17.0 of the Medical 
Dictionary for Regulatory Activities (MedDRA). Pharma-
cokinetic testing, quality of life questionnaires,13–15 an 
assessment of CNS-related symptoms (patients on prior 
efavirenz only),16–18 and FRAX evaluation19 were used in 
the study and will be reported elsewhere.
Statistical analysis
The primary effi  cacy endpoint was tested with a 
conventional 95% CI approach for the diff erence in 
response rates (tenofovir alafenamide group minus 
tenofovir disoproxil fumarate group); the lower bound of 
the 95% CI was assessed using a non-inferiority margin 
of 12%. All patients who were randomised and had 
received at least one dose of the study drug were included 
in the primary endpoint analysis (full analysis set). 
Assuming a 90% response rate for both groups 
at week 48, the power to establish non-inferiority ranged 
from 90% to 99% depending on the number of 
participating patients. It was intended to recruit 
1500 patients from the six prior studies and 1436 were 
randomised, the study had greater than 99% power to 
establish non-inferiority at week 48; the signifi cance level 
of the test was at a one-sided α of 0·025.
We summarise baseline characteristics with descriptive 
statistics. For categorical data, we calculated p values 
from the Cochran-Mantel-Haenszel test (general 
association statistic was used for nominal data, row mean 
scores diff er statistic was used for ordinal data). For 
continuous data, p value was from the two-sided 
Wilcoxon rank sum test.
For the primary endpoint, we constructed the 
percentage diff erences and the associated 95% CI with 
Mantel-Haenszel proportion,20 stratifi ed by previous 
treatment regimen. In the snapshot analysis of full 
analysis set, patients with HIV-1 RNA less than 50 copies 
per mL in the week 48 window (between days 294 and 
377) were classifi ed as a virological success. We classifi ed 
the following as virological failure: patients with HIV-1 
RNA of 50 or more copies per mL, patients with missing 
HIV-1 RNA data in the week 48 window, patients who 
discontinued study drug before week 48, or patients who 
changed treatment before week 48. A prespecifi ed 
superiority test was also done using the same 95% CI 
constructed for evaluating non-inferiority; if the lower 
bound of the 95% CI was greater than 0, superiority 
would be concluded.
We also analysed the primary effi  cacy endpoint by 
classifying missing data as failure, classifying missing 
data as excluded, and using the per-protocol analysis set; 
patients were included in the per-protocol if they received 
at least one dose of study drug unless they discontinued 
before week 48 or had an adherence rate in the lowest 
2·5 percentile. We repeated the primary endpoint 
analysis in the full analysis with a cutoff  of less than 
20 copies per mL. Changes in CD4 cell count from 
baseline to week 48 in the full analysis and per-protocol 
sets were summarised by treatment group with 
descriptive statistics using on-treatment data.
We summarised safety data in the full analysis set with 
descriptive statistics. For all secondary endpoint analyses, 
we pooled patients taking ritonavir-boosted atazanavir, 
emtricitabine, and tenofovir disoproxil fumarate and 
cobicistat-boosted atazanavir, emtricitabine, and teno-
fovir disoproxil fumarate to reduce non-relevant sub-
grouping. For key secondary endpoint safety data 
(percentage change in hip and spine bone mineral 
density, change from baseline in serum creatinine), we 
did prespecifi ed between-group comparisons at week 48 
with descriptive statistical testing. The diff erence in 
percentage change from baseline for spine and hip bone 
mineral density was constructed with an ANOVA model 
including previous treatment regimen as a fi xed eff ect. 
Articles
46 www.thelancet.com/infection   Vol 16   January 2016
We summarise the diff erence in serum creatinine 
separately for patients previously on efavirenz, 
emtricitabine, and tenofovir disoproxil fumarate and for 
patients previously on cobicistat or ritonavir boosted 
regimens; this was constructed with an ANCOVA model 
including previous treatment regimen as a fi xed eff ect 
and with baseline serum creatinine as a covariate. For 
percentage change from baseline in proteinuria, the 
diff erences between treatment groups were analysed 
using a Van Elteren test stratifi ed by previous treatment 
regimen. For other continuous laboratory test results, 
Wilcoxon rank sum testing was used. To control for the 
overall type 1 error rate in the primary effi  cacy endpoint 
assessment and the four key safety endpoints, we did 
hypothesis testing in sequential order with a protocol-
specifi ed fallback procedure. We used SAS version 9.2 
for all analyses.
An independent data monitoring committee was used. 
This study was registered with ClinicalTrials.gov, number 
NCT01815736.
Role of the funding source
Gilead Sciences funded the study, collected, and analysed 
the data, interpreted the results, and helped to write the 
report. AM had full access to the data, interpreted the 
results, and helped to write the report. All authors had 
full access to the data, could request additional analyses, 
and could provide input into the interpretation of results. 
AM, AKC, and SM made the decision to submit the 
manuscript for publication.
Results
Between April 12, 2013 and April 3, 2014, we randomly 
assigned 1443 patients; 1436 received at least one dose of 
study drug (fi gure 1). Of these 1436 patients, regimens 
received pre-randomisation were: elvitegravir 150 mg, 
cobicistat 150 mg, emtricitabine 200 mg, and tenofovir 
disoproxil fumarate 300 mg (n=459); efavirenz 600 mg, 
emtricitabine 200 mg, and tenofovir disoproxil fumarate 
300 mg (n=376); and cobicistat-boosted (n=216) or rito-
navir-boosted (n=385) atazanavir 300 mg, emtricitabine 
200 mg, and tenofovir disoproxil fumarate 300 mg. We 
randomly assigned 959 of these patients to switch to 
elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 
200 mg, and tenofovir alafenamide 10 mg (tenofovir 
alafenamide group). The remaining 477 patients remain-
ed on their previous tenofovir disoproxil fumarate-
containing regimen (tenofovir disoproxil fumarate 
group). 153 patients remained on elvitegravir, cobicistat, 
emtricitabine, and tenofovir disoproxil fumarate; 
125 remained on efavirenz, emtricitabine, and tenofovir 
disoproxil fumarate; 69 remained on cobicistat-boosted 
atazanavir, emtricitabine, and tenofovir disoproxil 
fumarate; and 130 remained on ritonavir-boosted ataza-
navir, emtricitabine, and tenofovir disoproxil fumarate. 
Baseline demographics were balanced between the two 
treatment groups with the exception of ethnic origin; 
more patients in the tenofovir alafenamide group than in 
the tenofovir disoproxil fumarate group reported 
Hispanic or Latino ethnic origin (p=0·0006; table 1). The 
two groups had similar probability of 10 year major 
osteoporotic fracture by FRAX estimation.19
At week 48, 932 (97%) of 959 patients in the tenofovir 
alafenamide group had virological success (HIV-1 RNA 
<50 copies per mL), compared with 444 (93%) of 
477 patients in the tenofovir disoproxil fumarate group 
(p=0·0002). The diff erence in percentage, adjusted by 
previous treatment regimen, was 4·1% (95% CI 1·6–6·7). 
Because the lower bound of this 95% CI was greater than 
the prespecifi ed 12% margin, the tenofovir alafenamide 
regimen was non-inferior to the tenofovir disoproxil 
fumarate-containing regimens. The lower bound was 
also greater than zero, and therefore the tenofovir 
alafenamide regimen was statistically superior to the 
tenofovir disoproxil fumarate-containing regimens. 
 Virological failures were similar between groups with 
ten (1%) in the tenofovir alafenamide group and six (1%) 
in the tenofovir disoproxil fumarate group (detailed in 
appendix). One (<1%) patient in the tenofovir alafenamide 
group had virological failure with genotypic resistance to 
a component of the treatment regimen. This patient had 
virological failure at week 8 with development of a 
Met184Ile/Met mixture; 4 weeks later this patient re-
suppressed to HIV-1 RNA less than 50 copies per mL 
without a change of regimen. More patients discontinued 
treatment for non-virological reasons in the tenofovir 
disoproxil fumarate group than in the tenofovir 
alafenamide group (appendix)
1559 patients screened
963 randomised 480 randomised
959 randomly assigned and treated 
 with TAF-containing regimen
32 discontinued
 9 had adverse event
 4 died
 1 had lack of efficacy
 2 at investigator discretion
 8 withdrew consent
 6 were lost to follow-up
 2 had non-compliance
40 discontinued
 12 had adverse event
 16 withdrew consent
 7 were lost to follow-up
 2 had non-compliance
 3 at investigator discretion
477 randomly assigned and treated 
 with TDF-containing regimen
925 continued on treatment† 435 continued on treatment†
4 never treated* 3 never treated*
Figure 1: Study profi le
*Four patients withdrew consent, two withdrew by investigator discretion, and one was lost to follow-up. 
†Four patients (two for each group) completed the randomised phase of the study and are now past week 96. 
TDF=tenofovir disoproxil fumarate. TAF=tenofovir alafenamide.
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In the per-protocol analysis, 913 (99%) of 921 patients in 
the tenofovir alafenamide group and 435 (99%) of 440 
patients in the tenofovir disoproxil fumarate group had 
virological success (percentage diff erence 0·3%). Results 
from the missing equals failure and missing equals 
excluded analyses were consistent with the primary 
endpoint (appendix). Rates of virological success in the 
full analysis set were similar for subgroups of age, sex, 
race, and geographic region (appendix). Virological 
success at a cutoff  of HIV-1 RNA less than 20 copies 
per mL was noted in 897 (94%) of 959 patients in the 
tenofovir alafenamide group and 431 (90%) of 477 patients 
in the tenofovir disoproxil fumarate group (adjusted 
percentage diff erence 3·2%, 95% CI 0·1–6·3). 
When the primary endpoint was calculated stratifi ed by 
previous treatment regimens, the proportion of patients 
with virological control varied. Of patients previously on 
elvitegravir, cobicistat, emtricitabine, and tenofovir 
disoproxil fumarate before randomisation, 98% (301 of 
306) who switched to tenofovir alafenamide maintained 
virological control, compared with 97% (149 of 153) who 
continued their regimen (percentage diff erence 1·0%; 
95% CI –1·9 to 3·9). Of patients previously on efavirenz, 
emtricitabine, and tenofovir disoproxil fumarate before 
randomisation, 96% (241 of 251) who switched to 
tenofovir alafenamide maintained virological control 
compared with 90% (112 of 125) who continued their 
regimen (percentage diff erence 6·4%, 95% CI 0·5–12·3). 
Of patients on boosted atazanavir plus emtricitabine and 
tenofovir disoproxil fumarate before randomisation, 97% 
(390 of 402) who switched to tenofovir alafenamide 
maintained virological control, compared with 92% (183 
of 199) who continued their regimen (percentage 
diff erence, 95% CI 0·9–9·2). 
Mean changes in CD4 cell counts were similar between 
groups: increase of 35 cells per μL (SD 165) for the tenofovir 
alafenamide group versus increase of 24 cells per μL 
(SD 156) for the tenofovir disoproxil fumarate group. 
Mean bone mineral density at the hip and spine 
increased in the tenofovir alafenamide group while 
remaining stable or decreasing at both sites in the 
tenofovir disoproxil fumarate group (p<0·0001; table 2). 
Hip and spine bone mineral density improved in patients 
assigned to the tenofovir alafenamide group compared 
with the tenofovir disoproxil fumarate group, irrespective 
of previous treatment. T-score bone mineral density for 
both hip and spine increased in patients assigned to the 
tenofovir alafenamide group, while remaining stable in 
those who continued their initial tenofovir disoproxil 
fumarate regimen (table 2). 
In a subset of patients who received 144 weeks of 
ritonavir-boosted atazanavir plus emtricitabine and 
tenofovir disoproxil fumarate in study GS-US-236-0103, 
mean percentage reduction in hip bone mineral density 
from baseline was 4·58% (SD 4·17).21 In this study, 
patients in this subset randomly assigned to the tenofovir 
alafenamide group (n=41) had improved hip bone 
mineral density by 1·35% (SD 3·07) whereas those 
remaining on prior treatment (n=13) had further 
reduction of 0·77% (SD 2·45). In this same subset, the 
mean percentage reduction in spine BMD in the previous 
Tenofovir alafenamide 
group (n=959)
Tenofovir disoproxil 
fumarate group (n=477)
Age (years) 41 (33–48) 40 (33–48)
Men 856 (89%) 427 (90%)
Women 103 (11%) 50 (10%)
Race
Native American 5 (1%) 2 (<1%)
Asian 59 (6%) 35 (7%)
Black 169 (18%) 102 (21%)
Native Hawaiian 6 (1%) 1 (<1%)
White 651 (68%) 314 (66%)
Ethnic origin
Hispanic or Latino 248 (26%) 82 (17%)
Baseline body-mass index (kg/m²) 25·8 (23·1–29·1) 26·1 (23·1–29·4)
HIV-1 RNA <50 copies per mL 943 (98%) 466 (98%)
CD4 count (cells per μL) 675 (520–833) 662 (525–831)
CD4 count categories
<50 cells per μL 0 0
50 to <200 cells per μL 5 (1%) 4 (1%)
200 to <350 cells per μL 54 (6%) 25 (5%)
350 to <500 cells per μL 151 (16%) 70 (15%)
500 cells per μL 749 (78%) 378 (79%)
Mode of infection (HIV risk factors)*
Heterosexual sex 216 (23%) 101 (21%)
Homosexual sex 753 (79%) 375 (79%)
Intravenous drug use 9 (1%) 5 (1%)
Transfusion 2 (<1%) 2 (<1%)
Vertical transmission 0 0
Other 8 (1%) 7 (1%)
Unknown 17 (2%) 12 (3%)
Estimated glomerular fi ltration rate by Cockcroft-Gault (CG) formula (mL per min)
Mean (SD) 111·9 (33·38) 112·1 (32·69)
Median 105·7 (89·4–126·0) 107·7 (88·7–128·2)
Estimated glomerular fi ltration rate by CKD-EPI creatinine formulation (mL per min per 1·73 m²)
Mean (SD) 92·8 (18·58) 92·7 (17·38)
Median 92·8 (101·0–123·3) 93·9 (102·5–123·5)
Proteinuria by urinalysis (dipstick)
Grade 0 873 (91%) 430 (90%)
Grade 1 81 (9%) 44 (9%)
Grade 2 4 (<1%) 3 (<1%)
10 year probability of hip fracture by FRAX (%)† 0·16% (0·04–0·43) 0·16% (0·04–0·47)
10 year probability of major osteoporotic fracture by 
FRAX (%)†
1·92% (1·20–3·07) 1·94% (1·17–3·27)
Data are median (IQR) or n (%), unless stated otherwise. Tenofovir alafenamide group assigned to receive a fi xed 
once-a-day dose of 150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 10 mg tenofovir alafenamide; 
the tenofovir disoproxil fumarate group was assigned to continue taking one of four previous regimens containing 
tenofovir disoproxil fumarate. CKD- CKD-EPI=chronic Kidney Disease Epidemiology Collaboration. *An individual 
patient could have more than one risk factor category. †For patients younger than 40 years (n=666; 436 patients in 
the tenofovir alafenamide group and 230 patients in tenofovir disoproxil fumarate group), the FRAX software 
calculated fracture probabilities at age 40 years. 
Table 1: Baseline demographics and disease characteristics for the safety analysis set
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study was 3·1% (SD 4·76); those assigned to the tenofovir 
alafenamide group (n=42) improved spine bone mineral 
density by 2·83% (SD 4·76) whereas those remaining on 
previous treatment (n=16) had further reduction of 
0·74% (SD 3·55%).
A greater number of patients in the tenofovir 
alafenamide group than in the tenofovir disoproxil 
fumarate group recovered from osteopenia or osteo-
porosis at either the hip or the spine during the 48 weeks 
(p<0·0001; fi gure 2). All reported fracture adverse events 
were the result of trauma and considered unrelated to 
treatment; no fragility fractures were reported.
Excluding patients switched from efavirenz, 
emtricitabine, and tenofovir disoproxil fumarate (an 
unboosted regimen), mean serum creatinine in those 
assigned to the tenofovir disoproxil fumarate group rose 
compared with the tenofovir alafenamide (2·9 μmol/L 
[SD 9·29] vs –0·4 μmol/L [10·14] in the tenofovir 
alafenamide group; diff erence in least squares mean for 
tenofovir alafenamide group versus tenofovir disoproxil 
fumarate group –3·33 μmol/L, 95% CI –4·57 to 
–2·10 μmol/L; p<0·0001). In patients who switched from 
efavirenz, emtricitabine, and tenofovir disoproxil fumarate 
to elvitegravir, cobicistat, emtricitabine, and tenofovir 
alafenamide, mean serum creatinine increased by 
9·2 μmol/L consistent with the established cobicistat eff ect 
on inhibition of serum creatinine excretion,22 whereas 
patients remaining on efavirenz, emtricitabine, and 
tenofovir disoproxil fumarate had a mean increase of 
1·77 μmol/L. eGFRCG values increased in the tenofovir 
alafenamide group (median 1·2 mL per min, 
IQR –6·6 to 9·1) compared with decreases from baseline in 
the tenofovir disoproxil fumarate group (–3·7 mL per min, 
IQR –10·5 to 3·5) between week 2 and week 48 (p<0·0001) 
after excluding patients on efavirenz, emtricitabine, and 
tenofovir disoproxil fumarate pre-randomisation.
General proteinuria and proximal tubular proteinuria 
decreased in patients assigned to the tenofovir 
alafenamide group, irrespective of previous treatment 
regimen, with signifi cant diff erences between the 
treatment arms beginning at week 2. By contrast, patients 
in the tenofovir disoproxil fumarate group had increases 
in each of these tests of proteinuria, with signifi cant 
diff erences between the groups noted throughout and 
at week 48 (p<0·001; appendix).
The tenofovir alafenamide regimen was well tolerated 
through a median of 82·9 weeks (IQR 72·1–84·3) of 
exposure, with nine (1%) patients discontinuing the drug 
due to adverse events and no drug-related serious adverse 
events (table 3). Patients in the tenofovir alafenamide 
group had a higher incidence of drug-related adverse 
events than did those in the tenofovir disoproxil fumarate 
group (21% vs 16%), but the types of adverse events were 
similar between the groups (table 3). 
Four patients died in the study, all in the tenofovir 
alafenamide group. One each died due to septic shock, 
stage 4 lung adenocarcinoma, and methamphetamine-
related myocarditis; one patient died from undetermined 
causes who had recent and substantial alcohol use; no 
deaths were considered treatment-related. Three patients 
in the tenofovir disoproxil fumarate group (all on boosted 
atazanavir) had jaundice leading to discontinuation. 
Kidney-related adverse events leading to treatment 
discontinuation were reported for two patients in the 
tenofovir alafenamide group and in fi ve patients in the 
tenofovir disoproxil fumarate group. No cases of proximal 
tubulopathy or Fanconi’s syndrome were reported ini the 
Figure 2: Changes in osteopenia and osteoporosis (T-score defi ned) from baseline to week 48
Diff erences between regimens were signifi cant (p<0·0001). TAF=tenofovir alafenamide. TDF=Tenofovir disoproxil 
fumarate
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Normal Osteopenia Osteoporosis
Tenofovir 
alafenamide 
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Tenofovir 
disoproxil 
fumarate group
Diff erence in least square 
means* (95% CI)
Hip BMD change
Number assessed 869 428 ··
BMD T-score change from baseline 0·11 (0·18) –0·02 (0·20) 0·13 (0·10–0·15); p<0·0001
Percent change from baseline 1·47% (2·71) –0·34% (2·83) 1·81 (1·49–2·13); p<0·0001
Patients with:
0–3% increase 486 (56%) 163/428 (38%) p<0·0001†
>3% increase 186/869 (21%) 32 (8%) ··
Spine BMD change
Number assessed 881 436
BMD T-score change from baseline 0·17 (0·29) –0·02 (0·31) 0·19 (0·16–0·23); p<0·0001
Percent change from baseline 1·56% (3·84) –0·44% (4·14) 2·00 (1·55–2·45); p<0·0001
Patients with:
0–3% increase 358/881 (41%) 146/436 (34%) p<0·0001†
>3% increase 291/881 (33%) 58/436 (13%) ··
Data are n/N (%) or mean (SD). Tenofovir alafenamide group assigned to receive a fi xed once-a-day dose of 150 mg 
elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 10 mg tenofovir alafenamide; the tenofovir disoproxil 
fumarate group was assigned to continue taking one of four previous regimens containing tenofovir disoproxil 
fumarate. BMD=bone mineral density. *Diff erence in least squares means and the 95% CI were calculated with analysis 
of variance model (ANOVA) in which current treatment and prior treatment were fi xed eff ects; p value from the 
Cochran-Mantel-Haenszel test. †p value from the Cochran-Mantel-Haenszel test.
Table 2: Changes in BMD in hip and spine from baseline to week 48 
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tenofovir alafenamide group; one patient from the 
tenofovir disoproxil fumarate group taking cobicistat-
boosted atazanavir, emtricitabine, and tenofovir 
disoproxil fumarate had Fanconi’s syndrome and needed 
discontinuation.
Laboratory abnormalities were similar in both 
treatment groups. Grade 3 or 4 abnormalities were noted 
in 244 (25%) patients in the tenofovir alafenamide group 
and 150 (31%) in the tenofovir disoproxil fumarate group 
(driven by the higher incidence of grade 3 or 4 hyper-
bilirubinaemia). Fasting lipid concentrations increased 
from baseline in the tenofovir alafenamide group but 
remained stable in the tenofovir disoproxil fumarate 
group (appendix). During the study, 76 (8%) patients in 
the tenofovir alafenamide group and 28 (6%) patients in 
the tenofovir disoproxil fumarate began lipid-lowering 
drugs.
Discussion
As far as we are aware, this was the largest randomised 
controlled switch study ever done in virologically 
suppressed patients with HIV. After establishing non-
inferiority of the tenofovir alafenamide regimen 
(elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 
200 mg, and tenofovir alafenamide 10 mg) to four 
tenofovir disoproxil fumarate-containing regimens 
at week 48, this study also showed that switching to the 
open-label tenofovir alafenamide regimen was also 
superior to continuing with the tenofovir disoproxil 
fumarate containing regimens. Both treatment groups 
had similar rates of virological failure at week 48, but 
more patients in the tenofovir disoproxil fumarate group 
had a last viral load less than 50 copies per mL and yet 
discontinued study drug due to other reasons. 
Patients previously on a regimen of efavirenz, 
emtricitabine, and tenofovir disoproxil fumarate or 
boosted atazanavir, emtricitabine, and tenofovir 
disoproxil fumarate regimens had signifi cant effi  cacy 
advantages when switched to the tenofovir alafenamide 
group. These advantages might have occurred because 
this was an open-label study: some patients might have 
been unwilling to tolerate efavirenz-related CNS side-
eff ects or atazanavir-related hyperbilirubinaemia. By 
contrast, patients who switched from tenofovir disoproxil 
fumarate to tenofovir alafenamide (remaining on 
elvitegravir, cobicistat, and emtricitabine) had similar 
rates of virological success at week 48 (98% vs 97%).
Treatments were well tolerated in both groups. The 
numerically higher frequency of adverse event reports 
for those switched to the tenofovir alafenamide regimen 
might be due to reporting bias in this open-label study in 
conjunction with a selection bias for those who continued 
their previous treatment regimen and were already 
tolerating it. Nonetheless, switching to the tenofovir 
alafenamide group showed several important safety 
advantages of tenofovir alafenamide over any of the 
tenofovir disoproxil fumarate-containing regimens.
Patients on prior tenofovir disoproxil fumarate-
containing regimens had improvements in their hip and 
bone mineral density after switching to the tenofovir 
alafenamide regimen. Previous data show that HIV-1 
infected patients who begin ART have a reduction in 
bone mineral density in the fi rst 24 to 48 weeks after 
starting treatment23,24 and this has been shown to be of 
higher magnitude with the use of tenofovir disoproxil 
fumarate-containing regimens.6,25,26
Little data on bone mineral density exist for patients 
switching ART regimens. In the OsteoTDF study, 
26 virologically suppressed patients switched from 
tenofovir disoproxil fumarate to abacavir and had hip 
density improve by 2·1% and spine density decrease by 
0·7% after 48 weeks.27 16 virologically suppressed patients 
Tenofovir 
alafenamide 
group (n=959)
Tenofovir 
disoproxil 
fumarate 
group (n=477)
Any adverse event 828 (86%) 399 (84%)
Study drug-related adverse event 204 (21%) 76 (16%)
Grade 3 or 4 adverse event 84 (9%) 54 (11%)
Serious adverse event 65 (7%) 35 (7%)
Study drug-related serious adverse 
event
0 2 (<1%)
Premature study drug discontinuation 9 (1%)* 12 (3%)†
Most common treatment-emergent 
adverse event
Upper respiratory tract infection 151 (16%) 54 (11%)
Diarrhoea 96 (10%) 42 (9%)
Nasopharyngitis 88 (9%) 39 (8%)
Headache 69 (7%) 20 (4%)
Cough 64 (7%) 25 (5%)
Syphilis 46 (5%) 30 (6%)
Insomnia 50 (5%) 30 (6%)
Arthralgia 59 (6%) 24 (5%)
Bronchitis 58 (6%) 26 (5%)
Depression 42 (4%) 30 (6%)
Osteopenia 56 (6%) 22 (5%)
Back pain 52 (5%) 25 (5%)
Nausea 50 (5%) 16 (3%)
Sinusitis 48 (5%) 25 (5%)
Data are n (%). Tenofovir alafenamide group assigned to receive a fi xed 
once-a-day dose of 150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, 
and 10 mg tenofovir alafenamide; the tenofovir disoproxil fumarate group was 
assigned to continue taking one of four previous regimens containing tenofovir 
disoproxil fumarate. *Adverse event-related discontinuations in one patient each 
from the tenofovir alafenamide group include: panic attack; memory loss, speech 
disturbance, and lack of motivation; acute renal failure; Reiter’s syndrome; 
nausea, vomiting, and headache; suicide attempt; leg swelling and impaired 
concentration; depression; and interstitial nephritis. †Adverse event-related 
discontinuations in one patient each from the tenofovir disoproxil fumarate 
group include: abnormal dreams; depression, insomnia, and irritability; 
depression, insomnia, and nightmares; elevated bilirubin; icterus (n=2); increased 
forgetfulness; chronic kidney disease; elevated serum creatinine; Fanconi’s 
syndrome and mild jaundice; increased creatinine; and nephritic colic.
 Table 3: Adverse events
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with HIV switched from two nucleoside reverse 
transcriptase inhibitors plus a protease inhibitor to 
protease inhibitor monotherapy and had a 0·2% increase 
for hip density and 0·08% decrease for spine density 
after 1 year.28 In a study of 37 patients with T scores lower 
than –1·0 who were taking a boosted protease inhibitor, 
switching from tenofovir disoproxil fumarate to 
raltegravir increased bone mineral density in the hip by 
2·5% and in the spine by 3·0% after 48 weeks.29 In this 
study of more than 1400 virologically suppressed patients, 
mean percentage change in hip and spine bone mineral 
density improved by 1·47% and 1·56% respectively. The 
fi ndings in the current study provide helpful information 
on the potential pathophysiology of tenofovir disoproxil 
fumarate-related changes in bone mineral density 
because they represent the largest body of data in a single 
study; switching to the tenofovir alafenamide regimen 
led to statistically signifi cant improvements irrespective 
of the third agent used with tenofovir disoproxil 
fumarate; switching to tenofovir alafenamide from 
tenofovir disoproxil fumarate while remaining on 
elvitegravir, cobicistat, and emtricitabine resulted in 
signifi cant improvement of bone mineral density. 
Moreover, T-score status for both hip and spine 
signifi cantly improved for those assigned to the tenofovir 
alafenamide group, and not to tenofovir disoproxil 
fumarate. Additional longer term follow up data are 
needed to assess the clinical relevance of these diff erences 
in bone mineral density.
The switch to tenofovir alafenamide also resulted in 
improvements in renal function, including decreases in 
serum creatinine (those switching from a boosted 
regimen), decreases in dipstick proteinuria, decreases in 
quantitative tests of total urine protein, and total urine 
albumin, decreases in specifi c proximal renal tubular 
proteins, and improvements in tests of proximal renal 
tubular function (fractional excretion of uric acid, fractional 
excretion of phosphate, and renal tubular maximum 
reabsorption rate of phosphate to the glomerular fi ltration 
rate; appendix). Proteinuria, albuminuria, and specifi c 
proximal tubular proteinuria have been shown to increase 
risk of mortality or cardiovascular events in both the 
general population and in HIV-1 infected individuals.30–34 
By signifi cantly reducing proteinuria, the switch to 
tenofovir alafenamide could aff ect mortality or 
cardiovascular events. Changes noted in renal laboratory 
tests occurred as early as week 2 after the switch from a 
tenofovir disoproxil fumarate-containing regimen and 
remained signifi cantly diff erent to week 48. Although the 
exact mechanism for these improvements is not known, it 
could be related to the lower plasma tenofovir con-
centrations in patients switched to tenofovir alafenamide.6 
Further, tenofovir is a substrate for transporters on the 
basolateral surface of proximal renal tubular cells (OAT1, 
OAT3) whereas tenofovir alafenamide is not.35 Therefore, 
although direct measurements were not made, patients 
switched to the tenofovir alafenamide-containing regimen 
probably had lower levels of tenofovir inside proximal 
renal tubular cells. Before entry into this study, all patients 
received at least 96 weeks of a tenofovir disoproxil 
fumarate-containing regimen. Chronic tenofovir disoproxil 
fumarate use can worsen kidney function, which is 
probably mediated through dysfunction in the proximal 
tubular cells.36–38 Although the renal safety implications for 
use of elvitegravir, cobicistat, emtricitabine, and tenofovir 
alafenamide in patients with pre-existing renal 
comorbidities are encouraging, the clinical relevance of 
improved renal parameters for patients who switched to 
tenofovir alafenamide regimens needs longer-term 
follow-up.
Increases in fasting total cholesterol, fasting LDL 
cholesterol, and fasting triglycerides were noted in the 
tenofovir alafenamide group, consistent with clinical 
data in patients who switch to a non-tenofovir disoproxil 
fumarate-containing ART regimen. Nonetheless, the 
total cholesterol to HDL ratio had only minimal changes 
from baseline. Compared with other regimens, use of 
tenofovir disoproxil fumarate has been linked to reduced 
lipids in treatment-naive patients than with other 
nucleoside reverse transcriptase inhibitors,39,40 potentially 
due to higher tenofovir concentrations in plasma. In this 
study and in two blinded and controlled studies in 
treatment-naive patients, patients on tenofovir 
alafenamide had slightly higher lipid concentrations 
than had those on tenofovir disoproxil fumarate.41,42 
Reported frequency of lipid-related or cardiovascular 
adverse events were similar between the two groups.
Limitations to these data do exist. This was an open-
label study in patients switching from a treatment 
regimen they were tolerating, and so caution is warranted 
in interpretation of the between-group diff erences in 
adverse event-related discontinuations and in subjective 
safety reports. Longer-term follow-up might be needed to 
understand the clinical advantages associated with the 
improvements in bone and renal safety observed in those 
switching to tenofovir alafenamide.
In conclusion, virologically suppressed HIV-1-infected 
patients who switched to a tenofovir alafenamide-
containing regimen (elvitegravir, cobicistat, emtricitabine, 
and tenofovir alafenamide) maintained virological 
suppression at a statistically higher rate at 48 weeks 
compared with those who remained on one of four 
tenofovir disoproxil fumarate-containing regimens 
(elvitegravir, cobicistat, emtricitabine, and tenofovir 
disoproxil fumarate; efavirenz, emtricitabine, and tenofovir 
disoproxil fumarate; cobicistat-boosted atazanavir plus 
emtricitabine and tenofovir disoproxil fumarate; or 
ritonavir-boosted atazanavir plus emtricitabine and 
tenofovir disoproxil fumarate). The tenofovir alafenamide 
regimen was well tolerated and patients had signifi cant 
improvements in bone and renal safety. Virologically 
supressed patients can be switched from tenofovir 
disoproxil fumarate-containing regimens to regimens 
containing tenofovir alafenamide without a loss of effi  cacy. 
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regimens to a regimen containing tenofovir alafenamide 
without loss of effi  cacy.
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